Macular structure and function after intravitreal injection of bevacizumab for wet macular degeneration a interventional study. - ND

POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI0 个研究点目标入组 20 人开始时间: 2006年6月23日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•Exudative age related macular degeneration age 60 and visual acuity between FC finger count and 0,5 decimal ETDRS table . The location of choroidal neovascularization CNV should be subfoveal either classic 4 disc diameter, minimally classic CNV or occult CNV, as well as RAP lesions more than II stage, lesions with large haemorrhagic component, large pigment epithelial detachments PED . Are also included in the study patients that are not eligible for photodinamic therapy PDT because they do not accomplish the PDT treatment criteria low vision, presence of disciform scar , or because they refuse PDT or other treatment for the cure of their pathology.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•Patients with exudative age related macular degeneration with classic CNV 4 disc diameter. Patients with exudative maculopathy CNV not related to age related macular degeneration such as pathologic myopia, inflammation, angioid streaks. Patients with media opacity in which is not possible to evaluate the details the fundus of the eye

发起方

POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI